Press releases & Latest news
Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…
Isofol reaches 440 patients in global Phase III AGENT study
GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…
Isofol presents an abstract at ASCO GI in January 2021
Isofol announces that an abstract, including arfolitixorin in the ISO-CC-005 study, has been accepted to be presented at ASCO GI…
Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data
Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM),…